GSK sees smokers return to patches, gum

Share this article:
GSK sees smokers return to patches, gum
GSK sees smokers return to patches, gum
GlaxoSmithKline is seeing a “leveling off of the impact” of Chantix on sales of its behind-the-counter nicotine replacement therapies (NRT) amid concerns about the safety of the smoking cessation drug.

The maker of Nicorette gum, Nicoderm CQ patches and Commit lozenges said sales of its NRT products took a hit with the debut of Chantix in August, 2006 as would-be quitters gave the novel Pfizer drug a try. But with worries about possible neuropsychiatric and other side effects of Chantix seizing headlines, GSK's NRT franchise is again seeing growth.

Advertising support for the GSK products is greater for this year than last, though budgeting preceded Chantix's recent troubles, a spokesperson said. In September, the “Tame the beast” TV ad campaign for the three brands, by Arnold Partners, will return to the air, and further advertising plans are in the works.
Pfizer pulled Chantix branded ads in January but is back on air with its unbranded “My time to quit” campaign. In May, the Wall Street Journal, citing Wolters Kluwer Health data, reported that new prescriptions for Chantix had fallen 55% since the beginning of the year.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.